#United States #New York #Securities Fraud #Rosen Law Firm #Cerevel Therapeutics

Opportunity for Class Action Against Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is currently facing a significant class action lawsuit stemming from allegations of securities fraud. The Rosen Law Firm, a prestigious global investor rights law firm, has drawn attention to the case and is encouraging all affected investors to join the class action. Below are the essential details and what you need to know if you sold or held shares during the class period from October 11, 2023, to August 1, 2024.

Who is Affected?

Investors who fit into the following categories may have grounds to participate in this lawsuit:
1. Individuals or entities that sold or disposed of common stock of Cerevel during the defined period.
2. Those who held shares as of the record date of January 8, 2024, and had voting rights on the merger with AbbVie Inc.
3. Investors who sold shares contemporaneously with Bain Capital's stock purchase around October 16, 2023.

With the deadline for lead plaintiffs approaching on June 3, 2025, it is essential for affected investors to act swiftly if they wish to join this case.

How to Join the Class Action

To participate in the class action lawsuit, individuals are instructed to visit Rosen Legal's website or contact Phillip Kim, Esq., toll-free at 866-767-3653. An email can also be sent to pkim@rosenlegal.com for inquiries related to the action. Notably, participation does not require any out-of-pocket fees due to a contingency fee arrangement.

The Basis of the Lawsuit

The allegations against Cerevel Therapeutics reveal a pattern of misleading statements made during their October 16, 2023, secondary stock offering and in the proxy statement released on January 18, 2024. It is claimed that Cerevel's controlling shareholders, Bain Capital and Pfizer Inc., strategically executed the stock offering at a discounted price to benefit Bain ahead of AbbVie's undisclosed acquisition agreement with Cerevel.

The lawsuit highlights that shortly after the offering, AbbVie announced a purchase of Cerevel for $45 per share—nearly double the offering price. This event resulted in Bain Capital earning over $120 million from the discounted shares purchased during the offering. As a result, numerous investors allegedly experienced financial losses when the true environment surrounding Cerevel's stock was unveiled to the market.

Why Choose Rosen Law Firm?

Rosen Law Firm emphasizes the importance of selecting experienced legal counsel when entering a class action. The firm has built a solid reputation in securities class action lawsuits, historically achieving successful settlements for clients, including the largest securities class action settlement involving a Chinese company at one time. In 2019, they secured over $438 million for their clients, demonstrating their commitment to protecting investors' rights.

The firm has consistently ranked at the top for the number of settled securities class actions and boasts several attorneys recognized in the legal community for their expertise in this practice area.

Next Steps for Investors

As the class has yet to be certified, individuals wishing to participate should consider their options carefully. They may choose to remain as absent class members and take no action, but doing so might limit their chances of participating in any prospective recovery. Should you wish to act as a lead plaintiff, moves must be made by the described deadline of June 3, 2025.

For further updates and information, you can follow Rosen Law Firm on their LinkedIn, Twitter, or Facebook.

With the class action underway and opportunities for eligible investors to reclaim losses, now is the time for those affected by the Cerevel situation to act. Make sure to stay informed and connected with resources that hold those accountable for any alleged misconduct.